MAAT PHARMA overview

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today provided a business update and reported its cash position as of June 30, 2023 and its revenues for the second quarter of 2023. "As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023. We are...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer , today announced that eClinicalMedicine has published clinical data on MaaT013 as a treatment for acute Graft-versus-Host Disease (aGvHD). The data includes results from 24 patients in a Phase 2 clinical trial and 52 patients enrolled in the Early...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer , today announced that the Company is now a member of Microbiome Therapeutics Innovation Group (MTIG). MTIG is a coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered on June 30 th , 2023, between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer , today announced new appointments to its Board and Executive team. Board of Directors Karim Dabbagh, PhD, is appointed as Chairman and independent Director, succeeding Jean-Marie Lefèvre who will continue to serve as a Board member. Based in the...